InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib...